Human Milk Oligosaccharides (HMO) Milk Powder Market Size, Share, Opportunities, And Trends By Type (2'-Fucosyllactose (2'FL), 3'-Fucosyllactose (3'FL), 3'-Sialyllactose (3'SL), 6'-Sialyllactose (6'SL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), Difucosyllactose (DFL)), By Application (Infant Formula, Dietary Supplements, Functional Foods and Beverages, Cosmetics), By Distribution Channel (Online Retailers, Supermarkets/Hypermarkets, Specialty Stores, Convenience Stores), And By Geography – Forecasts From 2025 To 2030

Human Milk Oligosaccharides (HMO) Milk Powder Market Size:

The Human Milk Oligosaccharides (HMO) Milk Powder Market is set to witness robust growth at a CAGR of 11.16% during the forecast period to be worth US$ 5.409 billion in 2030 from US$ 3.187 billion in 2025.

Human Milk Oligosaccharides (HMO) Milk Powder Market Trends:

The Human Milk Oligosaccharides (HMO) Milk Powder Market is experiencing robust demand due to the growing approval for the HMO milk powder from regulatory authorities. In August 2024, DSM-Firmenich announced the successful approval of its human milk oligosaccharide, 3-fucosyllactose (3-FL) and lacto-N-fucopentaose I/2'-fucosyllactose (LNFP-I/2'-FL) mixture. This approval is for the novel food ingredients in the United Kingdom and European Union. This is a significant development, opening up new possibilities for further product innovation and development. Additionally, the increased awareness about HMOs, such as improved gut health and immune support, is fueling market growth.

Human Milk Oligosaccharides (HMO) Milk Powder Market Growth Drivers:

The Human Milk Oligosaccharides (HMO) Milk Powder Market is witnessing significant growth driven by two major factors:

• The approval of HMOs in China for infant formula: HMOs are a significant solid component in human breast milk, after lactose and lipids. In October 2023, Chinese regulations permitted using HMOs in various formula types, including infant milk, boosting the market growth. Companies like Novonesis, one of the leading companies developing HMOs for the US and European markets, have started marketing their products in China as well. Other companies include International Flavours and Fragrance (IFF), DSM-Firmenich, and local milk producer Mengniu.
• Growing demand for infant formula in several countries: HMOs are rarely found in cow's milk or milk of other mammalian origin. The powdered infant formula market containing HMOs is continuously growing in Europe and the United States, but consumption is also expected to expand in China and Southeast Asia, where high population growth is anticipated. According to the United Nations Population Division, the average Southeast Asia for 2023, based on 11 countries, was 1.25 percent. The companies are aiming to expand their business to countries worldwide where there is a high demand for HMOs.

Human Milk Oligosaccharides (HMO) Milk Powder Market Segmentation Analysis by application

• Infant Formula: Infant formula has a notable market share driven by the growth of nutritional products for babies.
• Dietary Supplements: Increasing health awareness among a large population is driving this market.
• Functional Foods and Beverages: The growing trend for prebiotic and immune-boosting food and beverages increased the demand for HMOs.
• Cosmetics: The emerging skincare market of Asia Pacific has a significant demand for HMO products due to their beneficial properties.

Human Milk Oligosaccharides (HMO) Milk Powder Market Segmentation Analysis by distribution channel  

• Online Retailers: The online channel will grow significantly during the forecast period due to the growing internet penetration and smartphone usage.
• Supermarkets/hypermarkets: The growing economies will witness a significant increase in the development of supermarkets/hypermarkets.
• Specialty Stores: Specialty stores for nutrition-specific outlets are relevant to health-conscious consumers.
• Convenience Stores: Small retail stores will boost the demand for dietary supplements by increasing awareness about their benefits.

Human Milk Oligosaccharides (HMO) Milk Powder Market Geographical Outlook:

The Human Milk Oligosaccharides (HMO) Milk Powder Market report analyzes growth factors across the following five regions:

• North America: The market is driven by several prominent players based in the United States. These companies are crucial in product innovations and development, like infant formula, dietary supplements, functional foods, and beverages.
• Europe: The HMO milk powder market in Europe is driven by the growing number of health-conscious consumers and their emphasis on functional foods and beverages.
• Asia-Pacific: Rapid urbanization and increasing income in China, India, and Southeast Asia will fuel the market growth. Increasing awareness of the benefits of HMO milk powders is propelling the market. With rising disposable income, people are seeking a superior alternative to traditional food supplements.
• South America and MEA:  These emerging regions show growing interest in HMO milk powder for infant formula for their growing infant population.

Human Milk Oligosaccharides (HMO) Milk Powder Market – Competitive Landscape:

• Abbott- Similac 360 Total Care infant formulas by Abbott offer a blend of 5 HMOs. It is the closest prebiotic blend available to the HMOs found in breast milk. Pure Bliss by Similac infant formulas is a complete nutrition that is modeled after breast milk. It is available in a convenient ready-to-feed option.
• Kyowa Hakko Bio- Kyowa Hakko Bio is a subsidiary of Kirin Holdings Company Limited. In 2000, Kyowa Hakko Bio became the first company to establish an HMO industrial-scale mass-production system.
• FrieslandCampina- FrieslandCampina DOMO’s developed a new Human-like Milk Oligosaccharide (HMO) ingredient, 2’-fucosyllactose (2’-FL), in 2018 and had been officially certified to be used in infant formula in both European and U.S. markets. They supply HMO milk powder from their facilities, which are formulating and launching a broad range of HMOs.

These companies are at the forefront of developing and innovating HMO milk powder, contributing to market growth.

Human Milk Oligosaccharides (HMO) Milk Powder Market Latest Developments:

• In December 2024, Novonesis announced the approval of the first of its five commercialized HMOs in China. This is an important step towards the introduction of additional HMOs of its MyOli 5 HMO Mix.
• In November 2023, Nestlé launched its science-based growing-up milk solution containing HMOs (Human Milk Oligosaccharides) for early-life nutrition in mainland China under the Wyeth Illuma brand. This was followed by the recent approval for using such bioactives by the country's National Health Commission.

Human Milk Oligosaccharides (HMO) Milk Powder Market Scope:

Report Metric	Details
Human Milk Oligosaccharides Milk Powder Market Size in 2025	US$3.187 billion
Human Milk Oligosaccharides Milk Powder Market Size in 2030	US$5.409 billion
Growth Rate	CAGR of 11.16%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Type Application Distribution Channel Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Human Milk Oligosaccharides Milk Powder Market	BASF SE Abbott Laboratories Chr. Hansen Holding A/S DuPont de Nemours, Inc. DSM-Firmenich
Customization Scope	Free report customization with purchase

 

Human Milk Oligosaccharides (HMO) Milk Powder Market Segmentation:

By Type

• 2'-Fucosyllactose (2'FL)
• 3'-Fucosyllactose (3'FL)
• 3'-Sialyllactose (3'SL)
• 6'-Sialyllactose (6'SL)
• Lacto-N-tetraose (LNT)
• Lacto-N-neotetraose (LNnT)
• Difucosyllactose (DFL)

By Application

• Infant Formula
• Dietary Supplements
• Functional Foods and Beverages
• Cosmetics

By Distribution Channel

• Online Retailers
• Supermarkets/hypermarkets
• Specialty Stores
• Convenience Stores

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

 

Our Best-Performing Industry Reports:

• Infant Nutrition Market 
• Infant Formula Ingredients Market
• Milk Powder Market

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK 

5. HUMAN MILK OLIGOSACCHARIDES (HMO) MILK POWDER MARKET BY TYPE

5.1. Introduction

5.2. 2'-Fucosyllactose (2'FL)

5.3. 3'-Fucosyllactose (3'FL)

5.4. 3'-Sialyllactose (3'SL)

5.5. 6'-Sialyllactose (6'SL)

5.6. Lacto-N-tetraose (LNT)

5.7. Lacto-N-neotetraose (LNnT)

5.8. Difucosyllactose (DFL)

6. HUMAN MILK OLIGOSACCHARIDES (HMO) MILK POWDER MARKET BY APPLICATION

6.1. Introduction

6.2. Infant Formula

6.3. Dietary Supplements

6.4. Functional Foods and Beverages

6.5. Cosmetics

7. HUMAN MILK OLIGOSACCHARIDES (HMO) MILK POWDER MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Online Retailers

7.3. Supermarkets/hypermarkets

7.4. Specialty Stores

7.5. Convenience Stores

8. HUMAN MILK OLIGOSACCHARIDES (HMO) MILK POWDER MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India

8.6.4. South Korea

8.6.5. Taiwan

8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. BASF SE  

10.2. Abbott Laboratories 

10.3. Chr. Hansen Holding A/S 

10.4. DuPont de Nemours, Inc.

10.5. DSM-Firmenich 

10.6. Royal FrieslandCampina N.V.  

10.7. ZuChem, Inc. 

10.8. Inbiose NV 

10.9. Glycosyn LLC 

10.10. Kirin Holdings Company, Limited (Kyowa Hakko Bio)  

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

BASF SE 

Abbott Laboratories

Chr. Hansen Holding A/S

DuPont de Nemours, Inc.

DSM-Firmenich

Royal FrieslandCampina N.V. 

ZuChem, Inc.

Inbiose NV

Glycosyn LLC

Kirin Holdings Company, Limited (Kyowa Hakko Bio)